Article
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Molecular cancer therapeutics - 1 Aug 2016
Nakamura Yu, Togashi Yosuke, Nakahara Hirokazu, Tomida Shuta, Banno Eri, Terashima Masato, Hayashi Hidetoshi, de Velasco Marco A, Sakai Kazuko, Fujita Yoshihiko, Okegawa Takatsugu, Nutahara Kikuo, Hamada Suguru, Nishio Kazuto
Abstract excerpt
The prognosis for patients with advanced esophageal or head-and-neck squamous cell carcinoma (ESCC or HNSCC) remains poor, and the identification of additional oncogenes and their inhibitors is needed. In this study, we evaluated the sensitivities of several ESCC and HNSCC cell lines to HER inhibitors (cetuximab, erlotinib, and afatinib) in vitro and found two cell lines that were hypersensitive to afatinib....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.